NCT00861692

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

An Open-label, Multi-centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral antithrombotic therapy

Conditions

• Heparin-induced Thrombocytopenia Type II

Interventions

Type	Name	Description
DRUG	argatroban

Timeline

• Start date: 2009-04-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2009-03-13
• Last updated: 2026-01-06
• Results posted: 2015-12-22

Locations

1 site across 1 country: France